( LEXINGTON Mass.--(BUSINESS WIRE)--Apr ...)Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology,Health

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Critical Therapeutics, Inc. (Nasdaq: CRTX) today announced that new preclinical research demonstrating a role in chronic inflammatory autoimmune disease for High Mobility Group Box-1 protein (HMGB1), a pro-inflammatory mediator and nuclear DNA-binding protein, will be published in the May 2007 issue of Nature Immunology. The publication demonstrates that HMGB1 is part of DNA complexes that can stimulate immune cells to produce potent inflammatory mediators, which in turn can contribute to the inflammatory pathology of autoimmune disease. The work adds to the growing body of literature regarding the pro-inflammatory activity of HMGB1 and indicates a potentially important role for this protein in chronic inflammatory disease as well as in severe, acute systemic inflammatory disease, such as sepsis.

"The work described in the Nature Immunology article provides important new insight into the mechanism by which HMGB1 exerts pro-inflammatory activity," said Gregory LaRosa, Ph.D., Critical Therapeutics' Vice President of Discovery Research. "The preclinical data suggest that HMGB1 may contribute to the disease pathology of lupus and supplement earlier research suggesting that a therapeutic antibody to HMGB1 may provide protection in chronic inflammatory disease. As we work in collaboration with MedImmune, Inc., to develop monoclonal antibodies (MAbs) directed towards HMGB1, this new information as to how HMGB1 provides a pro-inflammatory stimulus will help guide our efforts."

The collaboration with MedImmune and Critical Therapeutics is working to discover and develop novel therapeutics for both severe, acute inflammation, and for chronic allergic and autoimmune inflammatory diseases. The collaborative HMGB1 therapeutic antibody project is one of the key development efforts at Critical Therapeutics, and with MedImmune, has made progress towards the identificatio
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
4. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
5. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
10. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients